These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 6895786)

  • 1. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
    Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical use of synthetic 1,25-dihydroxycholecalciferol.
    Evans IM; Boulton-Jones M; Doyle FH; Joplin GF; Lockwood M; Matthews EW; MacIntyre I
    Calcif Tissue Res; 1976 Aug; 21 Suppl():236-41. PubMed ID: 782663
    [No Abstract]   [Full Text] [Related]  

  • 6. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 7. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 8. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
    Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
    Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
    Chan JC; Lovinger RD; Mamunes P
    Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are new vitamin D analogues in renal bone disease superior to calcitriol?
    Salusky IB
    Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose vitamin D analogues for renal osteodystrophy.
    Lancet; 1989 Jun; 1(8651):1364-5. PubMed ID: 2567378
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
    Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
    N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency].
    von Herrath D; Kraft D; Grigoleit HG; Schaefer K
    Dtsch Med Wochenschr; 1973 Jul; 98(28):1379-81. PubMed ID: 4197778
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of renal osteodystrophy in predialysis patients.
    Sanchez CP; Goodman WG; Salusky IB
    Am J Med Sci; 1999 Jun; 317(6):398-404. PubMed ID: 10372840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Monitoring the calcium-phosphate product is important.
    McGregor MS; Rowe PA; Junor BJ
    BMJ; 1995 Jul; 311(6997):124; author reply 124-5. PubMed ID: 7613376
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal osteodystrophy in children with end-stage kidney failure.
    Chan JC
    Va Med; 1979 May; 106(5):384-90. PubMed ID: 463255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.